Answer
Campto (irinotecan) is contraindicated in patients with chronic inflammatory bowel disease and/or bowel obstruction.
Sources for this answer
- Campto 20mg/ml concentrate for solution for infusion (40mg presentation)Pfizer Limited · emc · SmPC §4.3 Contraindications · Version 27Document updated
Sources checked